Works matching IS 2160763X AND DT 2018 AND VI 7 AND IP 5


Results: 12
    1
    2
    3

    Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC.

    Published in:
    Clinical Pharmacology in Drug Development, 2018, v. 7, n. 5, p. 532, doi. 10.1002/cpdd.427
    By:
    • Tan, Eng‐Huat;
    • Lim, Wan‐Teck;
    • Ahn, Myung‐Ju;
    • Ng, Quan‐Sing;
    • Ahn, Jin Seok;
    • Shao‐Weng Tan, Daniel;
    • Sun, Jong‐Mu;
    • Han, May;
    • Payumo, Francis C.;
    • McKee, Krista;
    • Yin, Wei;
    • Credi, Marc;
    • Agarwal, Shefali;
    • Jac, Jaroslaw;
    • Park, Keunchil
    Publication type:
    Article
    4
    5
    6
    7
    9

    Issue Information.

    Published in:
    Clinical Pharmacology in Drug Development, 2018, v. 7, n. 5, p. 451, doi. 10.1002/cpdd.402
    Publication type:
    Article
    10
    11
    12